ArticleImmunologic research2009
Advances in treatment for chronic granulomatous disease.
Article in Immunologic research, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 50 citations in OpenAlex.
- Retroviral gene therapy for X-linked chronic granulomatous disease: results from phase I/II trial.Molecular therapy : the journal of the American Society of Gene Therapy · 2011Trial
- Noninfectious Manifestations and Complications of Chronic Granulomatous Disease.Journal of the Pediatric Infectious Diseases Society · 2018Review
- Clinical and molecular features of 38 children with chronic granulomatous disease in mainland china.Journal of clinical immunology · 2014Article
- Two X-linked chronic granulomatous disease patients with unusual NADPH oxidase properties.Journal of clinical immunology · 2011Article
- Allogeneic haematopoietic stem cell transplantation as therapy for chronic granulomatous disease--single centre experience.Journal of clinical immunology · 2011Article
- Gene therapy of chronic granulomatous disease: the engraftment dilemma.Molecular therapy : the journal of the American Society of Gene Therapy · 2011Review
- Residual NADPH oxidase and survival in chronic granulomatous disease.The New England journal of medicine · 2010Article
- Article
- In silico modeling indicates the development of HIV-1 resistance to multiple shRNA gene therapy differs to standard antiretroviral therapy.Retrovirology · 2010Article
- The relationship of x-linked primary immune deficiencies and autoimmunity.Current allergy and asthma reports · 2010Review
- Spontaneous Staphylococcus xylosus infection in mice deficient in NADPH oxidase and comparison with other laboratory mouse strains.Journal of the American Association for Laboratory Animal Science : JAALAS · 2010Article
- Successful unrelated donor cord blood transplantation for chronic granulomatous disease.International journal of hematology · 2010Article
- Chronic granulomatous disease.Clinical reviews in allergy & immunology · 2010Review
- Transplantation immunology: solid organ and bone marrow.The Journal of allergy and clinical immunology · 2010Review
- Atypical presentation of chronic granulomatous disease in an adolescent boy with frontal lobe located Aspergillus abscess mimicking intracranial tumor.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2010Article
- Improving cellular therapy for primary immune deficiency diseases: recognition, diagnosis, and management.The Journal of allergy and clinical immunology · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Chronic granulomatous disease (CGD) is a rare congenital disorder resulting from a failure of neutrophils to produce oxidases. Patients are therefore prone to recurrent infections from various organisms including fungi and atypical bacteria. The mortality in patients with the X-linked form of CGD, the most common type, ranges from 3% to 5% per year and although management of infections has improved with advances in antimicrobial therapies, better methods are needed to be able to cure these patients. Peripheral blood stem cell or bone marrow transplantation, while curative, is not widely used due to the episodic nature of the infections and the belief by many that conservative management is preferable to the risks of transplantation. Still, as will be discussed, improvements in the field are making allogenic transplantation more desirable and tilting the risk benefit ratio in favor of this modality. Additionally, gene therapy, which has been a long touted method to cure CGD, has within the last 5-10 years become more and more of a reality and may be realized by the end of this decade.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.